Skip to content

L-citrulline Supplementation During Sepsis

Arginine and Nitric Oxide (NO) Metabolism in Sepsis; L-citrulline Enteral Supplementation for the Normalisation of the Arginine-NO Metabolism

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00628381
Enrollment
48
Registered
2008-03-05
Start date
2011-01-31
Completion date
2013-01-31
Last updated
2010-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Organ Failure, Sepsis

Keywords

sepsis, microcirculation, nitric oxide, citrulline

Brief summary

The purpose of this study is to study the stimulating effects of prolonged (8h) enteral L-citrulline supplementation on the normalisation of the plasma citrulline concentrations and the Arginine-NO metabolism, the microcirculation, the systemic hemodynamics, vascular permeability, and organ function and disease severity scores.

Detailed description

NO synthesis is compromised during sepsis through lack of arginine de novo synthesis and may thereby contribute to impaired microcirculation and organ dysfunction. Supplementation of L-citrulline in septic patients will increase NO production without increased arginase activity and these effects will be studied on arginine-NO metabolism,improved organ function, vascular permeability and microcirculation.

Interventions

L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented

DIETARY_SUPPLEMENTL-alanine

L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Written informed consent from close relative * Age \> 18 years * Patient meets the general criteria for severe sepsis or septic shock, diagnosed less than 48 h prior to study inclusion. * Patient must be relatively hemodynamically stable, defined as stable blood pressure (variation in mean arterial pressure \<15 mm Hg) during 2h without necessity of increasing the vasopressor dose, inotropic support or rate of fluid administration. * Systemic arterial catheter in place with continuous pressure monitoring. * Patients in whom the clinician is prepared to provide full life support during the duration of the study

Exclusion criteria

* Shock due to any cause other than sepsis (e.g. drug reaction or drug overdose, pulmonary embolus, burn injury etc.) * Prolonged or high dose corticosteroid use * Liver cirrhosis * Chronic pancreatitis * Insulin-dependent diabetes mellitus * Metastases, haematological malignancies or chemotherapy * Patients on dialysis (CVVH or other) * Pre-existent renal failure (on dialysis)

Design outcomes

Primary

MeasureTime frame
To study stimulating effects of prolonged (8h) enteral L-citrulline supplementation on the normalisation of the arginine-NO metabolism8 hours

Secondary

MeasureTime frame
Secondary study endpoints are the microcirculation, the vascular permeability and organ function scores.within 8 hours

Countries

Netherlands

Contacts

Primary ContactNina Wijnands, MD, PhD-student
n.wijnands@ah.unimaas.nl+31-43-3884502
Backup ContactMartijn Poeze, MD, PhD
m.poeze@ah.unimaas.nl+31-43-3874425

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026